Miranda, Adam X.
Kemp, Justin
Davidson, Brad A.
Bellomo, Sara Erika
Miranda, Verda E.
Manoni, Alexandra
Marchiò, Caterina
Croessmann, Sarah
Park, Ben H.
Hodges, Emily
Funding for this research was provided by:
Vanderbilt-Ingram Cancer Center
Breast Cancer Research Foundation
Susan G. Komen Foundation
National Institutes of Health (CA214494, 1R01GM147078-01)
The Canney Foundation
Sage Patient Advocates
Marcie and Ellen Foundation
The Eddie and Sandy Garcia Foundation
Amy and Barry Baker
John and Donna Hall
Breast Cancer SPORE (NIH CA098131)
U.S. Department of Defense (W81XWH-20-1-0522)
American Cancer Society (#IRG-15-169-56)
Vanderbilt Stanley Cohen Innovation Fund
Article History
Received: 21 December 2023
Accepted: 2 May 2024
First Online: 27 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: C.M. reports personal consultancy fees from Bayer, Roche, AstraZeneca, Novartis, outside the scope of the present work. B.H.P. is a paid consultant for Guardant Health, AstraZeneca, Caris and is a paid scientific advisory board member for Celcuity Inc. B.H.P. is an unpaid consultant for Tempus Inc. B.H.P. also receives research funding from Eli Lilly and Guardant Health. Under separate licensing agreements between Horizon Discovery, LTD and The Johns Hopkins University, B.H.P. and S.E.C. are entitled to a share of royalties received by the University on sales of products. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict-of-interest policies. All other authors declare no competing interests.